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0.43–2.01; p = 0.85). However, biopsy strategy showed a 
shorter overall survival compared to wait-and-scan: hazard 
ratio of 2.69 (95% CI 1.19–6.06; p = 0.02). In this cohort 
we failed to confirm superiority of early resection over a 
wait-and-scan approach in terms of overall survival, though 
longer follow-up is required for final conclusion. Biopsy 
was associated with shorter overall survival.
Keywords Diffuse low-grade glioma · Wait-and-scan · 
Biopsy · Resection · Survival
Introduction
Diffuse low-grade gliomas (LGGs) are primary brain 
tumors that, due to their infiltrative nature, cannot be fully 
eradicated by resection, chemotherapy, radiation, or a com-
bination of these regimens. Most LGGs will gradually 
evolve into higher-grade gliomas and almost all patients 
will ultimately die from the disease [1, 2].
The typical LGG patient presents with a first epi-
leptic seizure and a lesion on MRI that is suspect for a 
LGG (isointense to hypointense and non-enhancing on 
T1-weighted images; hyperintense on T2-weighted and 
fluid attenuated inversion recovery (FLAIR) images) [3]. 
Consequently, in combination with clinical parameters, 
but yet without confirmed histology, physicians have to 
decide on a treatment strategy. They can opt for a wait-and-
scan policy, take a biopsy for histopathological verifica-
tion, or opt for immediate resection. Treatment strategy is 
patient dependent, influenced by the clinical condition of 
the patient, seizure control, size of the tumor and resect-
ability of the tumor [4]. An initial wait-and scan approach 
is usually followed by resection or biopsy at the time the 
lesion starts to show growth or enhancement on MRI, or 
Abstract Early resection is standard of care for presumed 
low-grade gliomas. This is based on studies including only 
tumors that were post-surgically confirmed as low-grade 
glioma. Unfortunately this does not represent the clini-
cians’ situation wherein he/she has to deal with a lesion 
on MRI that is suspect for low-grade glioma (i.e. without 
prior knowledge on the histological diagnosis). We there-
fore aimed to determine the optimal initial strategy for 
patients with a lesion suspect for low-grade glioma, but 
not histologically proven yet. We retrospectively identified 
150 patients with a resectable presumed low-grade-glioma 
and who were otherwise in good clinical condition. In this 
cohort we compared overall survival between three types 
of initital treatment strategy: a wait-and-scan approach 
(n = 38), early resection (n = 83), or biopsy for histopatho-
logical verification (n = 29). In multivariate analysis, no dif-
ference was observed in overall survival for early resection 
compared to wait-and-scan: hazard ratio of 0.92 (95% CI 
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when clinical deterioration occurs. Resection and biopsy 
can either be followed by a wait-and-scan policy, radio-
therapy, chemotherapy, or a combination of the latter two 
[4] Both chemotherapy and radiotherapy have been exten-
sively investigated in randomized controlled trials [5–11]. 
Controlled trials exploring the role and timing of surgery 
are lacking and, therefore, surgery for LGG has been con-
troversial for many years.
In the past an initial wait-and-scan approach was advo-
cated, since LGGs tend to grow slowly and patients usu-
ally present with controllable seizures as the only clinical 
symptom [12–14]. However, in the last 20  years, general 
opinion has shifted and early maximal resection is now 
widely accepted for patients with LGG-like lesions that are 
eligible for resection. Indeed, multiple retrospective studies 
showed that a more extensive resection is associated with 
a marked improvement of overall survival [15–23]. Also, 
a study in Norway showed that early resection significantly 
improves overall survival compared to a biopsy with a sub-
sequent watch-and-wait period [24, 25]. This growing bulk 
of evidence, although retrospective, has logically resulted 
in early maximal resection being standard of care and being 
incorporated in international guidelines nowadays [4].
However, we have to bear in mind that these retrospec-
tive studies are subject to at least some form of selection 
and indication bias. Firstly, these studies excluded the 
non-enhancing presumed LGGs that are diagnosed as a 
higher grade after early surgery. Secondly, these stud-
ies discarded the presumed LGGs that progressed to a 
higher grade during the wait-and-scan period. Thirdly, 
these studies included patients with confirmed LGG, but 
with preoperative enhancement on MRI, which is usually 
not a presumed low-grade glioma [26–28]. Possibly there 
is also indication bias present in these studies; the physi-
cians choice for initial treatment is potentially influenced 
by factors that also have impact on prognosis itself [29]. In 
conclusion, the cohorts used in these previous studies are 
not entirely representative for the daily clinical situation in 
which physicians are confronted with a LGG-like lesion on 
MRI without histological confirmation and, consequently, 
in combination with clinical parameters, have to decide for 
an initial treatment strategy. Therefore, a study with patient 
selection based solely on preoperative clinical and imaging 
characteristics is more clinically relevant and can add sig-
nificant evidence to support current daily clinical practice. 
A prospective trial is warranted but is unlikely to be con-
ducted due to the duration of such a study (median survival 
of ≥15 years in oligodendroglioma subtype [13]), ethical 
considerations raised by physicians who strongly believe 
in early resection, as well as obtaining patients’ consent to 
randomize between radically different treatment strategies.
In this retrospective study we approached the issue of 
treatment strategy from a more clinical and preoperative 
point of view and selected patients with a resectable LGG-
like lesion based on diagnostic imaging and not on histo-
pathological confirmation. We included those patients 
that we retrospectively consider equally eligible for either 
a wait-and-scan approach, a biopsy for histological veri-
fication, or early resection as initial treatment strategy; 
i.e. patients had to have limited neurological deficits that 
allowed a wait-and-scan strategy but also a LGG-like lesion 
that was eligible for extensive resection (estimation of at 
least 80% volume reduction possible, with use of current 
available techniques like awake surgery). In this manner 
we eliminated selection bias by histology and we avoided 
selection bias on indication as much as possible.
The aim was to determine the optimal initial treatment 
strategy for a resectable, presumed low-grade glioma by 
comparing overall survival between wait-and-scan, early 
resection and a biopsy approach.
Methods
Patient selection
Three large neurosurgical institutions participated in this 
cohort study, together serving a population of 6.5 million 
people in the southwest of the Netherlands. The institu-
tions involved were the Erasmus MC Cancer Institute in 
Rotterdam (EMC), Elisabeth-TweeSteden Hospital in Til-
burg (ETZ), and Medical Centre Haaglanden in The Hague 
(MCH).
We identified patients with a presumed LGG (LGG-
like lesion) that were retrospectively eligible for either ini-
tial treatment strategy: i.e. initial wait-and-scan approach, 
biopsy for histopathological verification, or immediate 
resection. Well-established prognostically favorable radio-
logical and clinical characteristics were used as inclusion 
criteria [30–32]. Radiological criteria were: supratentorial 
location of lesion, no contrast enhancement, no midline 
shift, maximal diameter <6  cm, sharply defined borders, 
and no involvement of corpus callosum, basal ganglia or 
thalamus. Clinical criteria were: age ≥ 18 years, Karnofsky 
Performance Status (KPS) >70, neurologically stable (with 
only epilepsy or minimal neurological deficits), and no 
dexamethasone dependency. Patients with active synchro-
nous cancer of other origin were excluded.
To identify glioma patients, the digital archives of 
patient letters were searched for all neurological and 
neurosurgical patients registered 1990–2010 in EMC, 
1996–2010 in ETZ, and 1992–2010 in MCH. In this first 
selection, high-grade gliomas were included so as not to 
exclude patients who progressed to a higher grade during 
a wait-and-scan period. In this search, of the 1115 glioma 
patients identified, a diagnostic scan could be retrieved for 
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498 of them, while the other part mainly originated from 
the pre digital era and was not available anymore. All diag-
nostic scans were reviewed to check if they met the criteria 
for (a) the radiological diagnosis of a low-grade glioma and 
(b) for the feasibility of an extensive resection (estimation 
of at least 80% volume reduction possible with modern 
surgical techniques like awake surgery) by a single neuro-
surgeon (AJPEV). Tumor near eloquent location was not 
an exclusion criterion per se, since the vast majority is eli-
gible for resection with modern surgical techniques. The 
reviewing neurosurgeon has more than 10  years’ experi-
ence in awake surgery and was blinded for clinical informa-
tion such as initial treatment strategy, the histopathological 
diagnosis and outcome. Of these 498 patients, 348 were 
excluded: 305 did not meet the radiological criteria, 21 did 
not meet the clinical criteria, and for 22 the complete medi-
cal records were not available. Eventually, 150 patients 
remained for analysis. An overview of the selection proce-
dure is shown in Fig. 1.
Study variables
Baseline characteristics of the patients were collected from 
the medical records and diagnostic scan; i.e. initial treat-
ment strategy, gender, age, KPS, presenting symptom, 
tumor location, mean tumor diameter and tumor eloquence; 
eloquence was graded with the criteria of Chang et al. [32].
Three types of initial treatment strategy were compared: 
initial wait-and-scan strategy after radiological diagnosis, 
early resection, and initial biopsy procedure for histologi-
cal verification. Treatment decisions were based on local, 
national and international guidelines in each individual 
centre at that time, by an experienced multidisciplinary 
team. Postoperative characteristics were also collected: first 
histology and grade, total number of resections, type of sur-
gery (awake vs. general anesthesia), subsequent strategy 
after early resection, or biopsy and administration of radio-
therapy and/or chemotherapy. Because postoperative MRI 
or CT scans were not available for most operated patients, 
the extent of resection could not be reliably investigated. 
In most tumors, molecular markers were not available and 
therefore not included in the analysis.
Outcome measure
The primary outcome measure was overall survival (OS), 
which was defined as the time between the diagnostic scan 
and death. All included patients were followed until death 
or censored at the date of last follow-up. Date of death 
was provided by patient records or the Municipal Personal 
Records Database.
Statistical analysis
All analyses were performed using R (3.1.3) and RStudio 
(0.99.486). Categorical data were analyzed with Pearson’s 
Chi square test or Fisher’s exact test when assumptions of 
the Chi square test were violated. Continuous data were 
analyzed with a Kruskal–Wallis test. Overall survival is 
shown in Kaplan–Meier plots (ggplot2 package in R). Uni-
variate and multivariate analyses were performed using a 
Cox proportional hazard model (survival CRAN pack-
age in R). All calculations were two-sided tests, with a p 
value <0.05 considered as statistically significant.
Fig. 1  Consort flow diagram 
of patient inclusion. Of the 
1115 glioma patients identi-
fied with a search in the digital 
patient archives, a diagnostic 
scan could be retrieved for 498 
of them. Of these, 305 were 
excluded as they did not meet 
radiological criteria, 21 did not 
meet clinical criteria, and for 
22 the complete medical record 
was not available. A total of 150 
cases remained for analysis
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Ethics and approvals
Need for informed consent was waived by the Medical Eth-
ical Committee of Erasmus MC, Rotterdam.
Results
The medical records and diagnostic scans of 498 identi-
fied glioma patients were screened with our selection crite-
ria to select patients with a resectable lesion and relatively 
favorable prognostic characteristics. A total of 150 patients 
with a resectable presumed LGG were included (Fig.  1). 
The initial treatment strategy was either an initial wait-
and-scan approach (n = 38), a biopsy for histopathological 
verification (n = 29), or early resection (n = 83). Median fol-
low-up was 7.1 years (25–75% interquartile range: 5.4–9.8 
years). Baseline characteristics were equally distributed 
between treatment groups, except for tumor location in elo-
quent area (15.8% in wait-and-scan vs. 10.3% in biopsy and 
32.5% in early resection; p = 0.02) (Tables 1, 2).
Median time between diagnostic scan and intervention 
was 35.4  months in the wait-and-scan group, 0.8  months 
in the biopsy group, and 2.9 months in the early resection 
group. In 80% (n = 66) of patients in the early resection 
group surgery was performed within 6  months after the 
diagnostic scan. Of the remaining 20% (n = 17), all received 
surgery within 1  year, without any sign of tumor growth, 
enhancement or clinical deterioration at time of surgery. In 
these latter patients the physicians’ initial choice of treat-
ment was an early resection. However, the time between 
diagnosis and resection was ≥6  months, mainly due to 
practical reasons; either because referral from the diagnos-
ing centre to neurosurgical centre was delayed, or due to 
patients’ doubts about the treatment strategy. Nevertheless, 
these 17 patients were not excluded from the analysis as the 
actual initial choice of treatment was early resection and 
the intervention took place when there was still no sign of 
clinical deterioration, tumor growth or contrast enhance-
ment on the control MRI. However to rule out bias, a sen-
sitivity analysis was performed with the exclusion of these 
patients (see below).
In the group with wait-and-scan as initial treatment strat-
egy, 79% of the patients eventually underwent a resection 
during follow-up. In these patients, surgery was initiated 
because of signs of growth or enhancement on follow-up 
imaging. There were no patients with uncontrolled sei-
zures in the wait-and-scan group, nor was this a reason 
for surgery during follow-up. In the biopsy group, 51.7% 
eventually underwent resective surgery. Distribution of 
the postoperatively obtained tumor characteristics (histol-
ogy and grade) differed between the groups: the biopsy 
group consisted of more astrocytomas (75.9 vs. 42.1% 
in wait-and-scan and 48.2% in early resection; p = 0.01) 
and the wait-and-scan group consisted of more gliomas 
of higher-grade (24.3 vs. 10.8% in resection and 3.4% in 
biopsy; p = 0.04).
Median OS in the early resection group was not reached 
and showed no significant difference (p = 0.42) from the 
wait-and-scan group in which the median OS was 11.9 
years (95% CI 9.5–∞) (Fig.  2). However, the median OS 
of 9.1 years (95% CI 5.8–∞) in the biopsy group was sig-
nificantly shorter compared to both the wait-and-scan and 
early resection group (log-rank test; p = 0.04 and p = 0.001, 
respectively) (Fig. 2).
Table 1  Patient characteristics at baseline
a Data are numbers (%) unless indicated otherwise
b Interquartile range (25–75%)
Characteristic Treatment strategy P
Wait-and-scan Early resection Biopsy
(N = 38) (N = 83) (N = 29)
N (%)a N (%)a N (%)a
Gender 0.14
 Male 25 (65.8) 40 (48.2) 18 (62.1)
 Female 13 (34.2) 43 (51.8) 11 (37.9)
Age in years
 Median  (IQRb) 38 (16.3) 39 (14.6) 41 (21.4) 0.14
 <40 23 (60.5) 46 (55.4) 13 (44.8) 0.43
KPS at diagnosis 0.28
 100 37 (97.4) 77 (92.8) 24 (82.8)
 90 1 (2.6) 5 (6.0) 4 (13.8)
 80 0 (0.0) 1 (1.2) 1 (3.4)
Presenting symptom 0.56
 Epilepsy 35 (92.1) 71 (85.5) 23 (79.3)
 Cognitive 
disorder
0 (0.0) 1 (1.2) 0 (0.0)
 Hemiparesis 0 (0.0) 1 (1.2) 2 (6.9)
 Speech disorder 0 (0.0) 1 (1.2) 1 (3.4)
 Incidental find-
ing
3 (7.9) 6 (7.2) 3 (10.3)
 Headache 0 (0.0) 3 (3.6) 0 (0.0)
Tumor location 0.94
 Frontal 18 (47.4) 46 (55.4) 13 (44.8)
 Temporal 7 (18.4) 14 (16.9) 6 (20.7)
 Parietal 5 (13.2) 11 (13.3) 4 (13.8)
 Occipital 1 (2.6) 1 (1.2) 0 (0.0)
 Insula 7 (18.4) 11 (13.3) 6 (20.7)
Eloquent area 0.02
 Yes 6 (15.8) 27 (32.5) 3 (10.3)
 No 32 (84.2) 56 (67.5) 26 (89.7)
Tumor diameter 
(mm)
 Median  (IQRb) 39.5 (12.0) 41.0 (16.5) 41.0 (10.0) 0.67
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In the univariate analysis, histology, grade, tumor loca-
tion and tumor eloquence also had a significant impact on 
OS (Table 3) and were, therefore, included in the multivari-
ate Cox regression. In this multivariate analysis, the dif-
ference in OS remained with a hazard ratio (HR) of 2.53 
(95% CI 1.1–6.1; p = 0.04) (Table 3) for the biopsy group 
compared to wait-and-scan, whereas no difference was 
observed for early resection compared to wait-and-scan 
(HR 0.92; 95% CI 0.43–2.01; p = 0.85).
A sensitivity analysis was also performed exclud-
ing those patients in the early resection group that did 
not undergo a resection within 6 months after diagno-
sis. No difference in OS was found for early resection 
compared to wait-and-scan with a HR of 0.70 (95% CI 
0.33–1.46; p = 0.34) in univariate analysis and 0.83 (95% 
CI 0.37–1.86; p = 0.65) in multivariate analysis (includ-
ing also histology, grade, and tumor location/eloquence 
as variables). A significant difference in OS remained for 
biopsy versus wait-and-scan, with a HR of 2.03 (95% CI 
1.03–3.99; p = 0.04) in univariate analysis and 2.82 (95% 
CI 1.24–6.43; p = 0.01) in multivariate analysis.
Discussion
Early maximal safe resection is considered standard of care 
for presumed LGG. Evidence to support this approach is 
mainly derived from retrospective studies; clear evidence 
from prospective trials for this early aggressive surgi-
cal approach is not available. Arguments in favor of early 
Table 2  Tumor and treatment 
characteristics of the three 
groups
a Data are shown as numbers (%)
b Treatment after intervention is shown for the groups in which the initial strategy was immediate resection 
or biopsy
Characteristics Treatment strategy P
Wait-and-scan Early resection Biopsy
(N = 38) (N = 83) (N = 29)
N (%)a N (%)a N (%)a
Number of resections <0.001
 Zero 8 (21.1) 0 (0.0) 14 (48.3)
 One 25 (65.8) 47 (56.6) 10 (34.5)
 Two 5 (13.2) 34 (40.9) 5 (17.2)
 Three 0 (0.0) 2 (2.4%) 0 (0.0)
Procedure of first surgery 0.36
 Awake 14 (46.7) 38 (45.8) 4 (26.7)
 General anesthesia 16 (53.3) 45 (54.2) 11 (73.3)
Subsequent treatment after initial 
resection or  biopsyb
<0.001
 Wait-and-scan Not applicable 53 (66.3) 3 (11.5)
 Radiotherapy Not applicable 26 (32.6) 22 (84.6)
 Other Not applicable 1 (1.3) 1 (3.8)
Ever radiotherapy 0.01
 Yes 28 (73.7) 57 (68.7) 28 (96.6)
 No 10 (26.3) 26 (31.3) 1 (3.4)
Ever chemotherapy 0.02
 Yes 23 (60.5) 30 (36.1) 16 (55.2)
 No 15 (39.5) 53 (63.9) 13 (44.8)
First histology 0.01
 Astrocytoma 16 (42.1) 40 (48.2) 22 (75.9)
 Oligodendroglioma 12 (31.6) 30 (36.1) 7 (24.1)
 Oligo-astrocytoma 9 (23.7) 13 (15.7) 0 (0.0)
 Not yet known 1 (2.6) 0 (0.0) 0 (0.0)
Grade 0.04
 II 28 (75.7) 74 (89.2) 28 (96.6)
 III 7 (18.9) 9 (10.8) 1 (3.4)
 IV 2 (5.4) 0 (0.0) 0 (0.0)
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resection include uncertainty about the radiological diagno-
sis, the assumption that resection will postpone malignant 
transformation and will improve overall survival [20, 26]. 
Indeed, several retrospective studies affirm the hypothesis 
that extensive resection for LGG improves overall survival 
[15–23]. Concerns that resection in a later stage of the dis-
ease could technically be more difficult and induce malig-
nant transformation are not unimaginable. In the light of 
these concerns and the association between extent of resec-
tion and overall survival, one may argue that the attempt for 
an extensive resection should be made as early as possible. 
These concerns that extent of resection can be influenced 
by timing of surgery in LGG have not been investigated by 
any study so far. Timing of treatment itself without incor-
poration of extent of resection has been studied before 
however. In a study by Jakola et  al., a unique situation in 
Norway was studied wherein treatment outcome was com-
pared between two centers: one centre favoured biopsy 
with subsequent watchful waiting strategy and the other 
centre early resection. The early resection strategy in one 
centre was clearly associated with a longer overall survival 
[24, 25]. For several years now, after years of controversy, 
the approach of early maximal resection logically is incor-
porated in treatment guidelines for LGG. However, despite 
current guidelines, we have to bear in mind those studies 
were biased by histopathological diagnosis as inclusion cri-
terion. This selection is actually not representative for the 
Fig. 2  Kaplan–Meier plot showing the overall survival per treatment 
strategy. The p value is calculated by the log-rank test including all 
three treatment groups. In the lower table, data indicate the numbers 
of patients at risk at the given time
Table 3  Univariate and 
multivariate analysis of 
overall survival using the Cox 
proportional hazards model
HR hazard ratio, ∞ infinite
Variable Univariate Multivariate
HR (95% CI) P HR (95% CI) P
Treatment
 Wait-and-scan 1 1
 Early resection 0.72 (0.36–1.46) 0.37 0.92 (0.43–2.01) 0.85
 Biopsy 2.04 (1.05–3.99) 0.04 2.69 (1.19–6.06) 0.02
Eloquency
 Yes 1 1
 No 2.36 (1.00–5.54) 0.05 1.41 (0.57–3.49) 0.46
Histology
 Astrocytoma 1 1
 Oligodendroglioma 0.40 (0.19–0.87) 0.02 0.49 (0.22–1.09) 0.08
 Oligo-astrocytoma 1.10 (0.52–2.30) 0.81 1.34 (0.58–3.11) 0.49
Grade
 >II 1 1
 II 0.49 (0.24–0.98) 0.04 0.40 (0.17–0.93) 0.03
Tumor location
 Frontal 1 1
 Temporal 3.40 (1.65–6.88) <0.001 3.49 (1.66–7.35) <0.001
 Parietal 1.90 (0.88–4.24) 0.10 1.60 (0.72–3.56) 0.25
 Occipital 0.00 (0.0–∞) 0.99 0.00 (0.00–∞) 0.99
 Insula 2.30 (1.03–4.94) 0.04 2.79 (1.21–6.40) 0.02
143J Neurooncol (2017) 133:137–146 
1 3
daily clinical setting whereby an initial treatment decision 
is based on imaging and patient characteristics. Although a 
prospective trial is the golden standard to clarify this issue, 
this is generally considered to be infeasible. We therefore 
tried to confirm the observations and assumptions from ear-
lier studies that early resection prolongs overall survival in 
a cohort that more closely mimics daily clinical situation.
The strength of the present study is that we selected 
patients in a way that was not done before. We included 
patients with a presumed LGG that were equally eligible 
for all three treatment strategies, by using preoperative 
characteristics typical for a prognostically favorable LGG, 
and not histopathological diagnosis. Survival was measured 
from the date of the first diagnostic scan. We consider this 
design to result in more clinically relevant conclusions than 
those of earlier studies, since our selection resulted in more 
unbiased inclusion and, therefore, a more equitable com-
parison of strategies compared to previous studies.
We observed no difference in OS between early resec-
tion and an initial wait-and-scan approach. This suggests 
that a wait-and-scan strategy can be safely proposed until 
evident growth, contrast enhancement or clinical deteriora-
tion occurs, and that the timing of surgery does not influ-
ence the prognosis. How to interpret this result? Similar 
findings have been found in other cancers with typically 
long survival times; early prostatectomy did not increase 
survival as compared to a watchful waiting policy in a large 
prospective trial in localized prostate cancer with 10 years 
follow-up [33, 34]. This trial shows that timing of the inter-
vention does not have the impact as expected. Overall sur-
vival is not influenced by early intervention as long as the 
patient is monitored and intervention takes place when 
necessary. Although our study was not set-up prospec-
tively, the results are comparable. It suggests that in tumors 
with relatively long overall survival, the relative short tim-
ing to treatment intervention is not influencing prognosis. 
The intrinsic biological behaviour of the tumor (molecular 
markers) has more impact than the timing of treatment. It 
also implies that potential morbidity of surgery or biopsy 
can be safely delayed in these patients and lead to higher 
quality of life until treatment [35]. On the other hand, sur-
gical techniques like awake craniotomy have been shown to 
be safe and could also decrease seizure frequency and med-
ication intake in patients with LGG. The data are however 
not mature yet to give final conclusions, but might already 
argue that a prospective trial is urgently needed to inves-
tigate if surgery can be safely delayed in a subset of pre-
sumed LGG patients.
In contrast to early resection versus wait-and-scan, this 
study shows that biopsy as initial strategy has a negative 
impact on OS. This observation is in line with that of the 
Norwegian study [24] and suggests that this strategy should 
be avoided. It is difficult to explain the significantly shorter 
OS for the biopsy group compared to the wait-and-scan 
group. In our cohort, we tried to select patients that were 
equally eligible for all treatment strategies. Nevertheless, 
we did observe a higher percentage of astrocytomas in the 
biopsy group, which may partly explain the poorer prog-
nosis. Alternatively, this difference in histology might be 
caused by sampling error in the biopsy group. Indeed, in 
a study examining histological diagnosis in paired biopsy 
and resection samples, an oligodendroglial component 
was missed in 50% of the biopsy samples [36]. If this is 
so, our study implies that biopsy is associated with a less 
favorable outcome. Moreover, in our multivariate analysis 
that corrected for histology, a worse prognosis remained 
for the biopsy group. Nevertheless, it cannot be ruled out 
that confounding factors that we missed/did not consider 
might have influenced physicians’ decision to choose for 
a biopsy procedure and, therefore, biased the selection for 
patients with poorer prognosis for the biopsy. To be on the 
safe side we think a biopsy should be avoided when pos-
sible. A negative effect of the biopsy itself seems unlikely 
although an acute inflammatory response induced by biop-
sies is reported to promote metastasis and proliferation in 
other types of cancer and recently it was shown in a murine 
model that reactive astrocytes can potentiate glioma aggres-
siveness after resection [37–40].
This study has a few limitations. First, this study is ret-
rospective in design. Although our selection criteria aimed 
to diminish the possible selection and indication bias which 
comes with such a design, bias is never ruled out com-
pletely. Also, the stringent selection criteria that were used 
resulted in a relatively small cohort size, but they were used 
to identify those patients in whom an extensive resection is 
possible according to current standards. Secondly, a longer 
follow-up is required before definite conclusions can be 
drawn, as we have not yet reached the median OS in the 
early resection group. Longer follow-up time is necessary.
Thirdly, the extent of resection also has an impact on 
OS [15–17, 20, 22, 23]. Perhaps the most important lim-
itation of our study is that the extent of resection was not 
measured in our cohort, since this might have influenced 
survival. Moreover, the awake craniotomy procedure that 
has emerged in glioma surgery, is reported to increase 
resection percentage and decrease morbidity compared 
to general anesthesia [41]. In our three treatment groups, 
the type of anesthetic procedure at the time of resection 
was chosen based on the best practice at that time. Of 
the 128 patients that had any resection during follow-
up, 56 (43%) were operated with an awake craniotomy 
procedure and the use of this procedure was equally dis-
tributed between the treatment groups. Given this equal 
distribution and the fact that we selected patients with a 
lesion eligible for extensive resection, it is unlikely that 
the extent of resection plays an explanatory role in our 
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results. It can never be ruled out however. Also, of the 
patients in the early resection group, 20% underwent 
the actual intervention within 6–12 months after the 
diagnostic scan. Nevertheless, as the initial choice of 
treatment by the physician was early resection and the 
intervention took place without any sign of clinical dete-
rioration, tumor growth or contrast enhancement on MRI 
scan, we decided not to exclude these patients from the 
analysis. The sensitivity analysis performed after exclu-
sion of these patients, failed to show different results.
It should be noted that there were imbalances in the 
treatment and tumor characteristics that were obtained 
after initial treatment decision, which should be taken 
into account when interpreting the data. The wait-and-
scan group consisted of more high-grade gliomas; this 
is, however, to be expected since the histological diagno-
sis in the wait-and-scan group was obtained at a median 
of 35.4 months after the initial imaging diagnosis. Also, 
there was an imbalance in chemotherapy administra-
tion, showing a lower percentage of patients exposed 
to chemotherapy in the early resection group. This is 
possibly explained by the fact that a significant part 
of the patients in the early resection group had a sub-
sequent wait-and-scan approach after initial resection. 
It is to be expected that also these patients will receive 
chemotherapy when follow-up is longer. On the other 
hand, although median follow-up in the early resection 
group is shorter, this might suggest that patients in the 
early resection group are more clinically stable than the 
other treatment groups. If this is so, we would expect 
the survival curves to further diverge with longer term 
follow-up.
Recently the WHO classification of tumors of the cen-
tral nervous system was updated and now incorporates 
molecular markers. This new classification outflanks 
classic histopathological classification in terms of prog-
nosis estimation and can also tailor therapy. Impact of 
surgery possibly differs between molecular subgroups, 
but this remains to be investigated. The integration of 
these markers in our study would be very interesting 
in the light of the new WHO classification. Unfortu-
nately, the status of these markers was not available for 
the majority of our population [42, 43]. However, these 
molecular markers are only determined after resection 
and should therefore not play a role in the selection and 
decision criteria of this study. New techniques are now 
developed to determine the molecular make up of pre-
sumed LGG on preoperative MRI’s [44]. This will hope-
fully lead to optimal treatment strategies of these tumors 
in the near future, which will also require further analy-
sis of the value of early and of extent of resection in the 
molecular glioma subtypes .
Conclusion
Investigation of three different treatment strategies in 
a clearly defined set of presumed LGG patients who 
were candidates for extensive resection could not con-
firm superiority of early resection over wait-and-scan. In 
agreement with previous studies, biopsy as first treatment 
strategy seems to be associated with significantly shorter 
overall survival. Still, this observation is difficult to 
explain. However, to be on the safe side, we think avoid-
ance of this strategy should be considered when possi-
ble. To our knowledge this is the first study to investigate 
treatment strategies for presumed LGG with this design 
based on preoperative imaging characteristics, which is 
highly representative for daily clinical presentation of 
this patient group. We need longer term follow-up upon 
final conclusion, but this data highlights prospective data 
is of vital importance.
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